証拠の質 4.75/5
8次元のレビュー評価。基準は 品質ルーブリック 。各次元は1〜5で評価。
- D1 出典への根拠
- 5/5
- D2 出典の権威性
- 5/5
- D3 算術
- 4/5
- D4 不確実性
- 4/5
- D5 範囲
- 5/5
- D6 文章
- 5/5
- D7 認識の誠実性
- 5/5
- D8 注意事項の完全性
- 5/5
● あなたの要因 — このリスクをクリック ▾ して表示
- あなたの要因
≈ 同じくらいの確率
認知リスク
肝臓がんは、一般の人々の心的モデルが最も較正されていないがん部位の一つである。豊かな国のほとんどの成人は、これをまれな、アルコール依存症者の病気として分類する——漠然と『悪いものの一つ』ではあるが、肺がんや乳がんのように真っ先に思い浮かぶ死因ではない。計算はこれに異を唱える。肝臓がんは**世界で3番目に多いがん死因**であり、肺と結腸直腸に次ぐだけで、乳房と胃を上回る。それが大きな差をつけて世界の上位5位以内に位置するのは、まさに支配的な駆動要因——慢性B型肝炎——が東アジアと東南アジア、そしてサハラ以南アフリカの多くで蔓延しているためであり、そうした地域ではそれが静かに世界最大級のがん死亡負担を生み出している。典型的な米国の読者はそれを脚注として目にするが、典型的な中国やベトナムの読者はそうではない。
概算: 米国成人の50%はがんになることを非常にまたはある程度心配している（Gallup、全部位）。肝臓がんは高所得国で名指しの心配事として認識されることはめったにない
出典: Gallup (2021) — Cancer, Heart Disease Worries Eclipse COVID-19
実際のリスク
世界で年間約758,000人の肝臓がん死（全がん死の約7.8%、第3位のがん死因）
世界、全年齢、肝臓および肝内胆管がん
計算を表示
世界で年間758,725人の肝臓がん死（新規症例866,136件）というGLOBOCAN 2022の推定を用いており、これにより肝臓がんは肺と結腸直腸に次いで世界で3番目に多いがん死因となる。約6.0 billionの世界の成人集団（18歳以上）にわたると、これは成人一人あたり年間およそ1,000あたり0.126の率である。素朴な60年の累積：1 − (1 − 0.000126)^60 ≈ 0.0075。これは下限値である。肝臓がんの死亡が60〜80歳の帯に大きく集中しているのに対し、素朴な累積はリスクを年齢一定として扱うためである。年齢加重すると現実的な世界の数値はおよそ0.015〜0.020に引き上げられる。見出しの0.017（≈ 60分の1）はその年齢加重した中間点に位置する。この世界平均をめぐる地域差は甚大である——低発生率の西欧諸国（北米の年齢調整死亡率は100,000あたり約6.7）と高発生率の東アジアの一部（年齢調整死亡率は100,000あたり約11〜14）との間でおよそ10倍——そしてそのほぼすべてが慢性B型肝炎感染の地理的分布によって駆動されている。肝臓および肝内胆管がんを発症する直接のSEER米国生涯数値は1.1%であり、5年生存率が約22%であることを踏まえると米国の生涯死亡率は0.7%に近い。見出しの数値は0.017（≈ 60分の1）であり、米国成人の下端と年齢加重した世界の上端を網羅するために0.007〜0.030の不確実性の幅を持つ。スコープはglobal-adult-lifetimeである。肝臓がんはLikelierのどのがん項目よりも地域間の差が大きく、米国のみの見出しはそれをひどく過小評価するためである。
注意事項: 肝臓がんは、当サイトのどのがんよりも地域間のばらつきが大きいLikelierの項目であり、単一の見出しの数値は読者の実際のリスクを要約する仕事を通常よりも下手に…
肝臓がんは、当サイトのどのがんよりも地域間のばらつきが大きいLikelierの項目であり、単一の見出しの数値は読者の実際のリスクを要約する仕事を通常よりも下手にこなす。約60分の1という世界の生涯数値は、東アジアとサハラ以南アフリカが世界の負担の不釣り合いに大きな割合を担い、北米と西欧が世界の年齢調整率のおよそ3分の1に位置する集団全体にわたる平均である。個人のリスクの最大の決定要因は慢性B型またはC型肝炎の状態であり、これは任意の個人にとって二値であり、生涯の数値を一桁以上動かす。米国の数値自体も動いている。ACSは、米国の肝臓がん発生率が過去40年間で3倍になったと報告しており、これは部分的にはHCVに曝露した1945〜1965年出生コホートによって、部分的には増大するNAFLD/MASLDの負担によって駆動されており、NAFLDコホートが高齢化するにつれて上昇し続けると予想されている。他方で、乳児への普遍的なHBVワクチン接種——ほとんどの国で1990年代以降ルーティン化——は、台湾、中国本土、その他の地域のワクチン接種後の出生コホートで、すでに発生率曲線を曲げ始めている。今後30年の世界の肝臓がんの構図は、ワクチン接種を受けたアジアのコホートにおけるHBV駆動の発生率の低下と、代謝的に不健康な西欧のコホートにおけるNAFLD駆動の発生率の上昇との不均一な混合である。最後に、ここでの『肝臓がん』は肝細胞癌（HCC）が支配的であり、これは世界の原発性肝臓がんの約80%を占める。肝内胆管癌やその他の亜型はSEERおよびGLOBOCANの見出しの数値でHCCと一括りにされているが、異なるリスク因子のプロファイルと予後を持つ。将来を見据えると、肝臓がんに関するランセット委員会（2025年7月）は、世界の負担がほぼ倍増すると予測している——新規症例は2022年の870,000件から2050年までに1.52 million件へ、死亡は760,000から1.37 millionへ——これはHBV（ワクチン接種コホートで減少中）よりも代謝およびアルコール関連疾患によって駆動される：症例のMASH帰属シェアは8%から11%へ、アルコール帰属シェアは19%から21%へ上昇するとモデル化され、2040年までに米国成人の55%超がMASLDを持つと予測されている。同委員会は、肝臓がんの少なくとも60%がHBV/HCVの制御とアルコールおよび代謝リスクの管理によって予防可能と判断しており、したがってこの予測される上昇は予報であると同時に政策上の選択でもある。これらのいずれも、2022年の負担に固定された現在の見出しの数値をここで変えるものではない。それは進む方向を鮮明にするものである。
リスクはどう変わるか
見出しの数値は大きく異なる状況の平均です。シナリオや文脈による確率の違いは以下の通りです:
67分の1 · 1.5%
~758K liver cancer deaths/yr across ~6B adults (GLOBOCAN 2022); age-weighted lifetime
25分の1 · 4.0%
Dominated by chronic hepatitis B; Eastern Asia alone accounts for roughly half of global liver cancer deaths, reflecting decades of endemic HBV transmission before the vaccination era
40分の1 · 2.5%
HBV plus dietary aflatoxin exposure; incidence is high but competing mortality and under-reporting make the absolute lifetime figure uncertain
143分の1
SEER lifetime diagnosis ~1.1%, 5-year survival ~22%, implied lifetime mortality ~0.7-0.9%; rising over the past four decades
125分の1
Lower than East Asia; burden increasingly driven by HCV legacy infection, alcohol, and NAFLD/MASLD rather than HBV
バーの長さと濃淡は、これらのシナリオを他のリスクとではなく、互いに比較して順位付けしたものです。正確な確率は各項目の横に表示されています。
関連するリスク
似たテーマの他のリスク — 関連する不安を探るために。
比較対象を選択
Liver cancer is the third leading cause of cancer death worldwide, and almost nobody in a wealthy country knows it. The IARC’s GLOBOCAN 2022 release puts the annual toll at 758,725 deaths — 7.8% of all global cancer deaths, behind only lung (18.7%) and colorectal (9.3%), and ahead of breast and stomach. Spread across a global adult population of roughly six billion and age-weighted for a normal 60-year adult lifespan, that works out to a lifetime mortality figure of about 1 in 60 for a generic adult alive today. For a US adult the number is much smaller: SEER puts the US lifetime risk of being diagnosed with liver or intrahepatic bile duct cancer at 1.1%, which combined with a 22% five-year survival gives a lifetime mortality closer to 0.7-0.9% — roughly one-fifth the age-standardised mortality rate of parts of Eastern Asia. The region-to- region spread is the largest of any cancer on this site.
What makes liver cancer an outlier in the Likelier catalogue is how tightly the global burden maps onto a single infectious agent. Chronic hepatitis B, rather than smoking or alcohol or diet, is by some distance the largest upstream driver. The WHO estimates 254 million people are living with chronic HBV worldwide and that hepatitis B caused about 1.1 million deaths in 2022, “mostly from cirrhosis and hepatocellular carcinoma.” Because HBV transmitted in infancy becomes chronic in roughly 95% of cases versus under 5% when acquired in adulthood, the geography of global HCC is effectively the geography of historical perinatal HBV transmission — which is why Eastern Asia alone accounts for roughly half of global liver cancer cases from about 30% of the world population. Taiwan’s 1984 universal infant HBV vaccination programme produced a ~70% reduction in childhood HCC within two decades, one of the cleanest cancer-prevention outcomes in the epidemiological literature. The hepatitis B vaccine is, in effect, a cancer vaccine. The perceived/actual gap here is wide enough that Likelier tags the entry underrated.
Where the number doesn’t apply: almost every specific reader. A vaccinated never-drinker with no chronic viral hepatitis runs a liver cancer mortality risk an order of magnitude below the US headline; a lifelong chronic HBV carrier with heavy alcohol use runs a risk an order of magnitude above it. The US number is also moving — ACS reports US liver cancer incidence has tripled over the past four decades, driven by the HCV-exposed 1945-1965 birth cohort and by the rising burden of non-alcoholic fatty liver disease (NAFLD, now often called MASLD). NAFLD is the emerging liver cancer driver in wealthy countries, tied to obesity, type 2 diabetes, and metabolic syndrome; the relative risk per person is much smaller than chronic HBV, but the exposed population is vastly larger, so the population-attributable fraction is rising. Direct-acting antivirals for HCV, introduced after 2013, have begun to reverse one of those pressures; the NAFLD pressure is still building. The next 30 years of the global liver cancer curve will be an uneven mix of vaccinated Asian cohorts aging out of the HBV era and metabolically-unwell Western cohorts aging into the NAFLD one.
関連する豆知識
肝臓がんは世界で成人およそ60人に1人の生涯の死因となり、世界で3番目に致死率の高いがんで、年間約758,000人が亡くなっている。高所得国では名指しのがんへの不安として浮上することはまれで、関心の隔たりは恐怖とは逆方向に働いている。
根拠台帳
以下の各数値は各出典が報告した内容であり、引用した原文の抜粋と算出方法を記載しています。リンクをクリックして直接確認できます。
-
[1] International Agency for Research on Cancer (IARC) / World Health Organization — New report on global cancer burden in 2022 by world region and human development level
New report on global cancer burden in 2022 by world region and human development levelSee all 3 Likelier entries citing this source →
- 統計値
In 2022 liver cancer was the third leading cause of cancer death globally (7.8% of all cancer deaths), behind lung (18.7%) and colorectal (9.3%)- 抜粋
“"the next most common causes were colorectal (9.3%) and liver cancer (7.8%)." ”
- 出典データ
- 2024-04-04
- アクセス日
- 2026-04-11 · アーカイブ版
- 計算過程
- IARC’s 7.8% of cancer deaths share, applied to ~9.7 million total annual global cancer deaths, gives ~760,000 liver cancer deaths per year — matching the GLOBOCAN 2022 direct estimate of 758,725 to two significant figures. Used to anchor the #3-cancer- killer framing in the body text.
- 独立性
- IARC GLOBOCAN is the upstream dataset that WHO and the cancer statistics literature draw from. Treat this source as partially dependent on the Bray 2024 CA paper and the Global Epidemiology PMC paper below — they all point at the same GLOBOCAN compilation.
-
[2] CA: A Cancer Journal for Clinicians (Bray, Laversanne, Sung, Ferlay, Siegel, Soerjomataram, Jemal) — Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries- 統計値
Liver cancer was the third leading cause of cancer death globally in 2022 with 7.8% of all cancer deaths (~760,000 deaths)- 抜粋
“"liver (7.8%)" [as the third leading cause of cancer deaths globally, following lung at 18.7% and colorectal at 9.3%] ”
- 出典データ
- 2024-04-04
- アクセス日
- 2026-04-11 · アーカイブ版
- 計算過程
- The Bray 2024 paper is the canonical peer-reviewed publication behind the GLOBOCAN 2022 release. It is the standard citation for the global-cancer-mortality ranking and is used here to anchor the "#3 cancer killer globally" framing. Liver cancer’s 7.8% share of global cancer deaths places it ahead of female breast (6.9%) and stomach (6.8%), two sites that get far more public attention in high-income countries.
- 独立性
- Bray et al. 2024 is the peer-reviewed publication of the GLOBOCAN 2022 compilation summarised in the IARC news item above. Treat as the same line of evidence, presented with different levels of detail.
-
[3] Journal of the National Cancer Center (via PubMed Central) — Global epidemiology of liver cancer 2022: An emphasis on geographic disparities
Global epidemiology of liver cancer 2022: An emphasis on geographic disparities- 統計値
866,136 new liver cancer cases and 758,725 deaths worldwide in 2022; global mortality-to-incidence ratio 0.86; Eastern Asia concentrates roughly half of global cases; Northern America incidence rate 6.7 per 100,000 vs Eastern Asia 14.7 per 100,000 age-standardised- 抜粋
“"In 2022, approximately 866,136 new liver cancer cases and 758,725 related deaths were recorded worldwide, with a global MIR of 0.86. [...] In China and East Asia, chronic hepatitis B virus (HBV) infection and aflatoxin contamination of food are prominent risk factors for liver cancer. [...] In high-HDI regions such as North America and Western Europe, factors such as chronic HCV infection, alcohol overconsumption, excess body fat, and type 2 diabetes may be more prominent contributors to liver cancer." ”
- 出典データ
- 2024-09-01
- アクセス日
- 2026-04-11 · アーカイブ版
- 計算過程
- This paper is the detailed 2022 liver-cancer-specific breakdown behind the GLOBOCAN headline numbers, and is the source for the regional_breakdown probabilities. The ~0.86 mortality-to-incidence ratio is the key prognosis metric: liver cancer kills ~86% of those diagnosed within a short horizon globally, reflecting late-stage diagnosis and limited curative treatment options in most populations. The Eastern Asia concentration (roughly half of global cases from ~30% of the world’s population) is the single largest regional disparity in the global cancer burden and the basis for the 10x East-Asia-vs-US multiplier in the body text.
- 独立性
- Draws on the same GLOBOCAN 2022 compilation as the Bray 2024 paper and the IARC news item; treat as partially dependent with respect to the headline death count. The regional breakdown and risk- factor discussion are the added value beyond the headline figures.
-
[4] US National Cancer Institute / Surveillance, Epidemiology, and End Results Program (SEER) — Cancer of the Liver and Intrahepatic Bile Duct — Cancer Stat Facts
Cancer of the Liver and Intrahepatic Bile Duct — Cancer Stat Facts- 統計値
US lifetime risk of being diagnosed with liver and intrahepatic bile duct cancer ~1.1%; ~42,240 new cases and ~30,090 deaths estimated for 2025; 5-year relative survival 22.0%; sixth leading cause of cancer death in the US- 抜粋
“"Approximately 1.1 percent of men and women will be diagnosed with liver and intrahepatic bile duct cancer at some point during their lifetime, based on 2018-2021 data. [...] The rate of new cases of liver and intrahepatic bile duct cancer was 9.4 per 100,000 men and women per year. [...] The death rate was 6.6 per 100,000 men and women per year. [...] 5-year relative survival: 22.0%." ”
- 出典データ
- 2025-04-01
- アクセス日
- 2026-04-11 · アーカイブ版
- 計算過程
- SEER is the methodological gold standard for US cancer lifetime risk. The 1.1% lifetime diagnosis figure (≈ 1 in 91) combined with a ~22% five-year survival gives an approximate US lifetime mortality of ~0.85%, which rounds to the ~0.7% figure used as the US lifetime anchor in the regional_breakdown table. The ~9.4 per 100,000 US incidence rate is less than half the global rate in Eastern Asia, which drives the order-of-magnitude regional spread. Used as the direct US anchor and as the prognosis anchor (22% five-year survival is one of the worst among common cancers, behind only pancreatic and oesophageal).
- 独立性
- SEER (NCI) is independent of IARC GLOBOCAN — SEER is US-only vital registration and population-based cancer registry data, IARC is a global compilation. Comparing the two anchors the US-vs-global gap.
-
[5] World Health Organization — Hepatitis B — fact sheet
Hepatitis B — fact sheet- 統計値
254 million people living with chronic hepatitis B infection globally in 2022; ~1.1 million hepatitis B deaths per year mostly from cirrhosis and hepatocellular carcinoma; perinatal HBV infection becomes chronic in ~95% of cases vs <5% in adult-acquired infection- 抜粋
“"In 2022, hepatitis B resulted in an estimated 1.1 million deaths, mostly from cirrhosis and hepatocellular carcinoma. [...] WHO estimates that 254 million people were living with chronic hepatitis B infection in 2022, with 1.2 million new infections each year. [...] Hepatitis B infection acquired in adulthood leads to chronic hepatitis in less than 5% of cases, whereas infection in infancy and early childhood leads to chronic hepatitis in about 95% of cases. [...] Some people with chronic hepatitis B will develop progressive liver disease and complications like cirrhosis and hepatocellular carcinoma (liver cancer)." ”
- 出典データ
- 2024-04-09
- アクセス日
- 2026-04-11 · アーカイブ版
- 計算過程
- WHO’s 1.1 million annual HBV deaths "mostly from cirrhosis and hepatocellular carcinoma" is the primary upstream source for the 25x chronic-HBV personal factor multiplier. Roughly half of global HCC cases are attributable to chronic HBV (the other half split between chronic HCV, alcohol, NAFLD/MASLD, and aflatoxin), and the 254 million chronic HBV carriers worldwide are concentrated in the same East/Southeast Asia and Sub-Saharan Africa regions that account for most global liver cancer mortality. The vaccinated multiplier of ~0.1 reflects the ~95% efficacy of the HBV vaccine in preventing chronic infection when administered in infancy — the intervention that has begun to bend the incidence curve in post-1980s cohorts in Taiwan, China, and elsewhere.
- 独立性
- WHO hepatitis B fact sheet draws on separate surveillance pipelines (WHO Global Hepatitis Programme, national seroprevalence surveys) from the IARC GLOBOCAN cancer registry pipeline. Treated as an independent line of evidence on the risk-factor side even though the downstream liver cancer mortality numbers are partially dependent via cause-of-death attribution.
-
[6] American Cancer Society — Key Statistics About Liver Cancer
Key Statistics About Liver Cancer- 統計値
~42,340 new US liver cancer cases and ~30,980 deaths projected for 2026 (27,790 new cases in men, 14,550 in women; 19,650 deaths in men, 11,330 in women); US liver cancer incidence has tripled over the past four decades- 抜粋
“"About 42,340 new cases (27,790 in men and 14,550 in women) will be diagnosed [...] About 30,980 people (19,650 men and 11,330 women) will die of these cancers [...] Liver cancer incidence rates have tripled in the US over the past 4 decades." ”
- 出典データ
- 2026-01-13
- アクセス日
- 2026-04-11 · アーカイブ版
- 計算過程
- ACS figures match SEER to within ~2% and are used as the annual US aggregate anchor. The more interesting number here is the three-fold increase in US liver cancer incidence over the past four decades — most of which is attributable to (a) the HCV infection cohort born 1945-1965, (b) rising rates of NAFLD/MASLD driven by obesity and metabolic syndrome, and (c) the ageing of the population. Used as the basis for the third body paragraph on NAFLD/MASLD as an emerging risk factor.
- 独立性
- ACS and SEER share the same underlying vital-registration and cancer-registry upstream (NCHS mortality data, NAACCR incidence data). Treat as one combined US line of evidence.
-
[7] EurekAlert! (AAAS) — official press release for The Lancet Commission on liver cancer — The Lancet: Three in five liver cancer cases due to preventable risk factors; obesity-linked cases on the rise, new analysis suggest
The Lancet: Three in five liver cancer cases due to preventable risk factors; obesity-linked cases on the rise, new analysis suggest- 統計値
Global liver cancer cases projected to nearly double from 870,000 (2022) to 1.52 million (2050) and deaths from 760,000 to 1.37 million; MASH-attributable share rising from 8% to 11% and alcohol-attributable from 19% to 21%; over 55% of US adults could have MASLD by 2040; at least 60% of liver cancers are preventable- 抜粋
“"the number of new liver cancer cases will nearly double from 870,000 in 2022 to 1.52 million in 2050. [...] The number of deaths from liver cancer are predicted to grow from 760,000 in 2022 to 1.37 million in 2050. [...] the proportion of liver cancer cases associated with MASH are projected to increase from 8% in 2022 to 11% in 2050 [...] liver cancer cases associated with alcohol are projected to increase from 19% in 2022 to 21% in 2050 [...] by 2040, over 55% of US adults could have MASLD." ”
- 出典データ
- 2025-07-28
- アクセス日
- 2026-06-14 · アーカイブ版
- 計算過程
- This is a forward projection (2050 horizon), not a revision of the current GLOBOCAN 2022 mortality used for the headline figure, so it does not change normalized.lifetime_us_adult — it is cited to support the forward-projection caveat and to strengthen the MASLD/MASH and alcohol personal-factor narratives. The Lancet Commission's 2022 baseline (870,000 cases / 760,000 deaths) is consistent with the GLOBOCAN 2022 figures already anchoring this entry (866,136 cases / 758,725 deaths) to within rounding. The MASH share rising 8%->11% and alcohol 19%->21% are attributable-fraction projections, not relative-risk estimates, so they do not yield a new multiplier value.
- 独立性
- The Lancet Commission draws on the same GLOBOCAN/GBD compilation as the IARC and Bray sources for its 2022 baseline; treat its baseline death count as partially dependent. The 2050 projection and the attributable-share modelling are the added value beyond the existing headline figures.